Kindstar Globalgene Technology, Inc. completed its global offering and listing on The Stock Exchange of Hong Kong Limited, raising gross proceeds of approximately US$285.2 million (which could rise to US$328 million if the over-allotment option is exercised in full).
Kindstar Globalgene is a leading clinical testing service provider, with the largest esoteric testing portfolio among all independent esoteric testing providers in China.
S&C acted as Hong Kong and U.S. counsel to the joint sponsors and underwriters, including Goldman Sachs, CICC and Credit Suisse.
The S&C team was led by Ching-Yang Lin and Kay Ian Ng in Hong Kong and Gwen Wong in Beijing and included Stephen Pang, Johnny Han and Guanlin Wang.